Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Foralumab - Tiziana Life Sciences

Drug Profile

Foralumab - Tiziana Life Sciences

Alternative Names: NI-0401; NI-0401/α-CD3; TZLS-401

Latest Information Update: 10 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medarex; NovImmune SA
  • Developer Light Chain Bioscience; NovImmune SA; Tiziana Life Sciences
  • Class Anti-inflammatories; Antidementias; Antihaemorrhagics; Antihyperglycaemics; Hepatoprotectants; Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease; Multiple sclerosis
  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Haemorrhage; Type 1 diabetes mellitus
  • No development reported Cytokine release syndrome; Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Type 2 diabetes mellitus
  • Discontinued Transplant rejection

Most Recent Events

  • 08 Jan 2024 Efficacy data from an expanded access program in Multiple sclerosis released by Tiziana Life Sciences
  • 05 Jan 2024 Tiziana Life Sciences files for patent protection for foralumab and GLP-1ra combination therapy
  • 28 Dec 2023 No recent reports of development identified for phase-I development in Cytokine release syndrome(Combination therapy) in Brazil (Intranasal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top